Skip to content
Open access

The Utility of Faecal Biomarkers in the Discrimination Between Acute Gastroenteritis and Inflammatory Bowel Disease

Aug 2026 · Biomedicines · Vol 14, pp. 1951 · 0 citations · 31 references
Medicine

TL;DR

Faecal biomarkers reflecting neutrophil, eosinophil, and epithelial activity may provide complementary information in the differentiation of patients with suspected acute GE and new-onset IBD, suggesting that faecal HNL may have the ability to distinguish between these conditions.

Abstract

Background: Acute infectious gastroenteritis (GE) and inflammatory bowel disease (IBD) may have similar clinical characteristics at onset, and discrimination between these two diagnoses can initially be challenging. Aim: To explore faecal biomarkers reflecting neutrophil, eosinophil, and epithelial activity to distinguish between acute GE and IBD onset. Methods: Faecal samples were collected from patients presenting with acute GE (n = 28), treatment-naïve patients with newly diagnosed IBD (n = 40), and healthy controls, HC (n = 40). Faecal biomarkers, including faecal calprotectin (FC), myeloperoxidase (MPO), human neutrophil lipocalin (HNL), eosinophil cationic protein (ECP), and eosinophil-derived neurotoxin (EDN), were assessed by ELISA. The Kruskal–Wallis test was used for biomarker comparisons. To evaluate the discriminative capability of biomarkers, receiver operating characteristic (ROC) curves were established. Result: Patients with acute GE displayed elevated levels of all the tested biomarkers compared with HC (p < 0.001). Higher levels of faecal HNL (p < 0.001), EDN (p < 0.01), and MPO (p < 0.05) were seen in acute GE patients than in patients with newly diagnosed IBD. HNL yielded the highest discriminative capability between acute GE and IBD with AUC 0.74, 95%CI: 0.62–0.84. Conclusions: This exploratory study suggests that faecal biomarkers may provide complementary information in the differentiation of patients with suspected acute GE and new-onset IBD. Our findings indicate that faecal HNL may have the ability to distinguish between these conditions. However, given the exploratory design and limited sample size, findings should be interpreted with caution, and the discriminative value of HNL and the other biomarkers requires further validation in larger, well-characterised acute GE cohorts.

Read PDF

Similar papers

Open access Sep 2026

From blood to bowel: correlating serological markers with mucosal healing and inflammation in patients with inflammatory bowel disease

Background Inflammatory bowel disease (IBD) is a systemic disease characterized by chronic inflammation of the gastrointestinal tract. Serological testing has the advantages of wide sources and easy detection. Objective To explore the correlation between the serological markers and endoscopic mucosal healing and histol...

Yi Zhang, Ze-Cheng Zhang, Hui-Ling Sun et al. · 0 citations
Review Open access Oct 2026

The Role of Fecal Biomarkers in Monitoring Crohn’s Disease: Innovations in Diagnosis and Management

Crohn’s disease (CD) requires continuous assessment of inflammatory activity to support treat-to-target strategies and prevent progressive bowel damage. Although endoscopy remains the reference standard, its invasive nature limits repeated use, emphasizing the need for reliable non-invasive biomarkers. This narrative r...

C. Petcu, A. Treteanu, O. Andronic et al. · 0 citations
Open access Sep 2026

Changes in circulating microRNAs and inflammatory proteins in children with celiac disease during the first year on a gluten-free diet.

BACKGROUND & AIMS In celiac disease (CD), mucosal recovery can only be assessed through biopsy, as current serological tests do not reliably reflect histological status or residual inflammation after gluten withdrawal. This limitation is particularly relevant in children, in whom invasive procedures are preferably avoi...

Gesala Perez-Junkera, Naroa Altolaguirre, A. Lasa et al. · 0 citations
Open access Sep 2026

Connecting the Dots Between Pharmacokinetics, Inflammatory Biomarkers, and Mucosal Healing in Patients on Infliximab with Inflammatory Bowel Disease

Background/Objectives: Mucosal healing (MH) is a key therapeutic target in inflammatory bowel disease (IBD) associated with sustained remission, reduced hospitalisation, and improved outcomes. Its assessment relies on endoscopic evaluation, which is invasive, costly, and not always feasible. Therapeutic drug monitoring...

A. Homšek Ilić, M. Jovanović, S. Marković et al. · 0 citations
Review Open access Aug 2026

Interpreting Biomarker Discordance in Inflammatory Bowel Disease: Beyond Fecal Calprotectin and C-Reactive Protein

Treat-to-target management in inflammatory bowel disease (IBD) combines symptoms, fecal and serum biomarkers, endoscopy, histology, and cross-sectional imaging, but these measures frequently diverge. Discordance may reflect analytical variation, timing, disease location, phenotype, comorbidity, or partially non-overlap...

Lovre Martinović, Roko Šantić, M. Kumrić et al. · 0 citations
Open access Sep 2026

Serum NGAL and S100A12 as Biomarkers of Active Disease in Ulcerative Colitis

Aim: To investigate the potential use of serum neutrophil gelatinase-associated lipocalin (NGAL) and S100A12 (S100 calcium-binding protein A12) as biomarkers for determining disease activity in ulcerative colitis (UC) within the same study.Materials and Methods: The study included individuals from the active (n=34) and...

Orhan Çiçek, Fatih Kamış, Özge Kurtkulağı et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.